HRP20240166T1 - Postupak liječenja prader-willijevog sindroma - Google Patents
Postupak liječenja prader-willijevog sindroma Download PDFInfo
- Publication number
- HRP20240166T1 HRP20240166T1 HRP20240166TT HRP20240166T HRP20240166T1 HR P20240166 T1 HRP20240166 T1 HR P20240166T1 HR P20240166T T HRP20240166T T HR P20240166TT HR P20240166 T HRP20240166 T HR P20240166T HR P20240166 T1 HRP20240166 T1 HR P20240166T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- use according
- carbetocin
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462052957P | 2014-09-19 | 2014-09-19 | |
| EP19216650.2A EP3666258B1 (en) | 2014-09-19 | 2015-09-14 | Method of treating prader-willi syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240166T1 true HRP20240166T1 (hr) | 2024-04-26 |
Family
ID=54238564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240166TT HRP20240166T1 (hr) | 2014-09-19 | 2015-09-14 | Postupak liječenja prader-willijevog sindroma |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10441627B2 (OSRAM) |
| EP (2) | EP3193907B1 (OSRAM) |
| JP (3) | JP6599447B2 (OSRAM) |
| CN (2) | CN112773765A (OSRAM) |
| CA (1) | CA2957224A1 (OSRAM) |
| DK (1) | DK3666258T3 (OSRAM) |
| ES (2) | ES2775425T3 (OSRAM) |
| FI (1) | FI3666258T3 (OSRAM) |
| HR (1) | HRP20240166T1 (OSRAM) |
| HU (1) | HUE065829T2 (OSRAM) |
| LT (1) | LT3666258T (OSRAM) |
| PL (1) | PL3666258T3 (OSRAM) |
| PT (1) | PT3666258T (OSRAM) |
| RS (1) | RS65144B1 (OSRAM) |
| SI (1) | SI3666258T1 (OSRAM) |
| WO (1) | WO2016044131A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6599447B2 (ja) | 2014-09-19 | 2019-10-30 | フェリング ベスローテン フェンノートシャップ | プラダー・ウィリー症候群を治療する方法 |
| WO2019030412A1 (en) | 2017-08-11 | 2019-02-14 | Ferring B.V. | PROCESS FOR PRODUCING PHARMACEUTICAL PREPARATION |
| WO2019032946A1 (en) | 2017-08-11 | 2019-02-14 | Ferring B.V. | PROCESS FOR PRODUCING OXYTOCIN |
| US10736894B2 (en) | 2018-02-15 | 2020-08-11 | Ovid Therapeutics Inc. | Methods of treating developmental syndromes with PDE10A inhibitors |
| CN114288253B (zh) * | 2018-09-20 | 2024-04-02 | 阿卡蒂亚药品公司 | 稳定的鼻内卡贝缩宫素制剂 |
| KR20210062648A (ko) | 2018-09-20 | 2021-05-31 | 레보 테라퓨틱스 인코포레이티드 | 카르베토신 완제의약품 및 이를 제조하는 방법 |
| JP2024500401A (ja) * | 2020-12-18 | 2024-01-09 | ザ ジェネラル ホスピタル コーポレイション | 小児の成長および社会的機能を強化するためのプロバイオティクス組成物およびその使用方法 |
| AU2022242768A1 (en) | 2021-03-26 | 2023-10-19 | Centre Hospitalier Universitaire De Toulouse | Treatment of dysphagia |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7544662B2 (en) | 1993-06-17 | 2009-06-09 | Carle Development Foundation | Polypeptides useful for appetite suppression |
| US6894026B1 (en) * | 2000-01-11 | 2005-05-17 | Atossa Healthcare, Inc. | Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders |
| US20070032410A1 (en) | 2000-01-11 | 2007-02-08 | Atossa Healthcare, Inc. | Compositions and methods for the treatment of psychiatric disorders |
| US9023793B2 (en) | 2006-09-29 | 2015-05-05 | Retrophin, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| WO2008150305A1 (en) * | 2007-06-07 | 2008-12-11 | Nastech Pharmaceutical Company Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| CA2704724A1 (en) | 2007-09-11 | 2009-04-16 | Mondobiotech Laboratories Ag | 5use of a peptide as a therapeutic agent |
| WO2009043436A2 (en) | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of af12198 as a therapeutic agent |
| US20100190717A1 (en) | 2007-09-11 | 2010-07-29 | Dorian Bevec | Use of melanin concentrating hormone and met-enkephalin as therapeutic agents |
| WO2009033820A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| SI2260053T1 (sl) * | 2008-03-31 | 2014-08-29 | Ferring Bv | Analogi oksitocina |
| WO2010009374A1 (en) | 2008-07-18 | 2010-01-21 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
| TWI463990B (zh) * | 2009-09-21 | 2014-12-11 | Ferring Bv | 催產素受體促進劑 |
| US20120108510A1 (en) | 2010-05-20 | 2012-05-03 | Emory University | Methods of improving behavioral therapies |
| WO2011147889A1 (en) | 2010-05-25 | 2011-12-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of a feeding disorder with early-onset in a patient |
| JO3400B1 (ar) * | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
| WO2012149472A2 (en) | 2011-04-27 | 2012-11-01 | Ignite Institute For Individualized Health | Methods, compositions, and kits for treating and preventing neurological conditions |
| HRP20181569T1 (hr) * | 2012-12-21 | 2018-11-30 | F. Hoffmann - La Roche Ag | Peptidi kao agonisti oksitocina |
| EP2945624B1 (en) | 2013-01-17 | 2018-04-18 | F.Hoffmann-La Roche Ag | Oxytocin receptor agonists for the treatment of cns diseases |
| EA030091B1 (ru) | 2014-06-03 | 2018-06-29 | Ф. Хоффманн-Ля Рош Аг | Пептиды, выполняющие роль агонистов окситоцина |
| CR20160562A (es) | 2014-06-06 | 2017-01-06 | Hoffmann La Roche | Péptidos como agonistas de la oxitocina |
| KR20170040231A (ko) | 2014-08-07 | 2017-04-12 | 에프. 호프만-라 로슈 아게 | 옥시토신 유사체의 제조 방법 |
| JP6599447B2 (ja) | 2014-09-19 | 2019-10-30 | フェリング ベスローテン フェンノートシャップ | プラダー・ウィリー症候群を治療する方法 |
-
2015
- 2015-09-14 JP JP2017515228A patent/JP6599447B2/ja active Active
- 2015-09-14 PT PT192166502T patent/PT3666258T/pt unknown
- 2015-09-14 US US15/510,781 patent/US10441627B2/en active Active
- 2015-09-14 SI SI201531990T patent/SI3666258T1/sl unknown
- 2015-09-14 HU HUE19216650A patent/HUE065829T2/hu unknown
- 2015-09-14 CN CN202110278199.4A patent/CN112773765A/zh active Pending
- 2015-09-14 WO PCT/US2015/049911 patent/WO2016044131A1/en not_active Ceased
- 2015-09-14 LT LTEP19216650.2T patent/LT3666258T/lt unknown
- 2015-09-14 PL PL19216650.2T patent/PL3666258T3/pl unknown
- 2015-09-14 ES ES15772107T patent/ES2775425T3/es active Active
- 2015-09-14 FI FIEP19216650.2T patent/FI3666258T3/fi active
- 2015-09-14 HR HRP20240166TT patent/HRP20240166T1/hr unknown
- 2015-09-14 CN CN201580049147.2A patent/CN106714819A/zh active Pending
- 2015-09-14 CA CA2957224A patent/CA2957224A1/en active Pending
- 2015-09-14 DK DK19216650.2T patent/DK3666258T3/da active
- 2015-09-14 RS RS20240134A patent/RS65144B1/sr unknown
- 2015-09-14 EP EP15772107.7A patent/EP3193907B1/en active Active
- 2015-09-14 EP EP19216650.2A patent/EP3666258B1/en active Active
- 2015-09-14 ES ES19216650T patent/ES2970059T3/es active Active
-
2019
- 2019-10-02 JP JP2019181930A patent/JP6921154B2/ja active Active
- 2019-10-03 US US16/592,632 patent/US20200129584A1/en not_active Abandoned
-
2021
- 2021-03-15 JP JP2021041334A patent/JP2021098745A/ja active Pending
-
2022
- 2022-11-18 US US18/057,065 patent/US20240082344A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3193907A1 (en) | 2017-07-26 |
| SI3666258T1 (sl) | 2024-04-30 |
| LT3666258T (lt) | 2024-01-10 |
| RS65144B1 (sr) | 2024-02-29 |
| FI3666258T3 (fi) | 2024-02-09 |
| CN106714819A (zh) | 2017-05-24 |
| JP6599447B2 (ja) | 2019-10-30 |
| ES2970059T3 (es) | 2024-05-24 |
| JP2017532316A (ja) | 2017-11-02 |
| EP3666258A1 (en) | 2020-06-17 |
| CN112773765A (zh) | 2021-05-11 |
| PL3666258T3 (pl) | 2024-04-08 |
| JP2021098745A (ja) | 2021-07-01 |
| ES2775425T3 (es) | 2020-07-27 |
| EP3193907B1 (en) | 2020-01-01 |
| JP6921154B2 (ja) | 2021-08-18 |
| DK3666258T3 (da) | 2024-02-05 |
| JP2020019790A (ja) | 2020-02-06 |
| CA2957224A1 (en) | 2016-03-24 |
| PT3666258T (pt) | 2024-02-01 |
| US10441627B2 (en) | 2019-10-15 |
| US20240082344A1 (en) | 2024-03-14 |
| HUE065829T2 (hu) | 2024-06-28 |
| US20200129584A1 (en) | 2020-04-30 |
| US20170326200A1 (en) | 2017-11-16 |
| EP3666258B1 (en) | 2023-11-15 |
| WO2016044131A1 (en) | 2016-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240166T1 (hr) | Postupak liječenja prader-willijevog sindroma | |
| HRP20250181T1 (hr) | Spojevi i postupci za ciljanu razgradnju receptora androgena | |
| HRP20250250T1 (hr) | Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji | |
| HRP20220759T1 (hr) | Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti | |
| MX2016016593A (es) | Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos. | |
| MY180145A (en) | Cenicriviroc compositions and methods of making and using the same | |
| HK1201828A1 (en) | Treatment regimens using multiple pharmaceutical agents | |
| AU2017312811A8 (en) | Liquid naloxone spray | |
| HRP20241552T1 (hr) | Acetil-leucin ili njegova farmaceutski prihvatljiva sol za poboljšanu pokretljivost | |
| EA201992382A2 (ru) | Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| EP4385563A3 (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine | |
| MY198553A (en) | Pharmaceutical composition comprising metformin and lobeglitazone | |
| GR1008228B (el) | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου | |
| HRP20180316T1 (hr) | Izolirani čvrsti oblik anamorelin monohidroklorida s niskim molarnim odnosom klorida: anamolerina i niskim sadržajem rezidualnog organskog otapala | |
| MX2016009475A (es) | Composiciones efectivas contra la conjuntivitis viral. | |
| MY196333A (en) | Intranasal Composition Comprising Betahistine | |
| AR084195A1 (es) | Formulacion de un complejo que comprende clorhidrato de lercanidipina y valsartan y metodo para la preparacion de la misma | |
| MX2015006356A (es) | Formulacion de capsula de acido 5-aminosalicilico. | |
| MX374223B (es) | Preparacion de complejo que incluye valsartan y rosuvastatina calcica y metodo de fabricacion para el mismo. | |
| PH12013501896A1 (en) | Use of a sprayable composition comprising ambroxol | |
| HRP20192028T1 (hr) | Arginin, namijenjen upotrebi u liječenju i/ili sprječavanju osteoartritisa | |
| PH12020550597A1 (en) | Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt | |
| GR1008380B (el) | Φαρμακευτικο σκευασμα περιεχον ενα αντιικο παραγοντα και μεθοδος για την παρασκευη αυτου | |
| PH12019501607A1 (en) | Tapentadol nasal composition |